Table 2 Results of the subdistribution hazard regression (Fine and Gray) models for both type of failures

 Age^a

0.96 (0.75–1.23)

0.121

0.95 (0.67–1.35)

0.132

 Stage

  III

1

1

  IV

2.43 (1.58–3.73)

0.026

2.66 (1.47–4.81)

0.021

 Grade

  1

1

1

  2

1.24 (0.97–1.59)

0.037

1.36 (0.99–1.94)

0.088

  3

1.57 (1.03–2.39)

0.024

1.89 (1.04–3.43)

0.031

 Histology

  Serous

1

1

  Mucinous

0.93 (0.82–1.05)

0.095

0.95 (0.79–1.14)

0.118

  Clear cell

1.43 (1.02–2.01)

0.036

1.68 (1.14–2.48)

0.029

  Endometrioid

0.96 (0.82–1.12)

0.102

0.98 (0.89–1.07)

0.095

  Others^d

2.17 (1.65–2.85)

0.028

2.36 (1.67–3.34)

0.025

 Type of chemotherapy

  intravenous

1

1

  intraperitoneal

0.78 (0.67–0.91)

0.029

0.82 (0.70–0.96)

0.031

 GOG performance status

   ≤ 1

1

1

   ≥ 2

0.83 (0.68–1.02)

0.075

0.92 (0.81–1.06)

0.079

 Charlson comorbidity index

  0

1

1

   ≥ 1

0.84 (0.68–1.04)

0.083

0.88 (0.70–1.09)

0.089

 Age^a

0.95 (0.91–0.99)

0.038

0.92 (0.87–0.97)

0.017

 Stage

  III

1

1

  IV

0.92 (0.77–1.11)

0.337

0.87 (0.69–1.04)

0.214

 Grade

  1

1

1

  2

0.87 (0.65–1.16)

0.298

0.91 (0.64–1.29)

0.348

  3

0.92 (0.59–1.47)

0.361

0.87 (0.55–1.37)

0.229

 Histology

  Serous

1

1

  Mucinous

1.06 (0.89–1.26)

0.139

1.07 (0.85–1.35)

0.168

  Clear cell

1.01 (0.76–1.18)

0.106

1.05 (0.86–1.28)

0.143

  Endometrioid

0.95 (0.82–1.10)

0.295

0.98 (0.79–1.21)

0.315

  Others^d

0.91 (0.81–1.02)

0.082

0.89 (0.75–1.05)

0.091

 Type of chemotherapy

  Intravenous

1

1

  Intraperitoneal

0.89 (0.73–1.22)

0.127

0.94 (0.81–1.09)

0.115

 GOG performance status

   ≤ 1

1

1

   ≥ 2

1.05 (0.84–1.38)

0.229

1.03 (0.82–1.36)

0.226

 Charlson comorbidity index

  0

1

1

   ≥ 1

0.77 (0.65–0.92)

0.022

0.79 (0.66–0.94)

0.027